Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-01 |
{
"resourceType" : "Evidence",
"id" : "236975",
"meta" : {
"versionId" : "61",
"lastUpdated" : "2024-10-03T13:11:20.368Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 236975</b></p><a name=\"236975\"> </a><a name=\"hc236975\"> </a><a name=\"236975-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 61; Last updated: 2024-10-03 13:11:20+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-comparative-evidence.html\">ComparativeEvidence</a></p></div><p><b>url</b>: <a href=\"Evidence-236975.html\">Evidence MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</a></p><p><b>identifier</b>: FEvIR Object Identifier/236975, outcomeId/313963, picoId/85798, sectionId/73215, <a href=\"http://terminology.hl7.org/6.0.2/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.22.66</p><p><b>version</b>: 2.0.0-ballot</p><p><b>name</b>: Serious_hyperglycaemiafrom_MAGICapp_313963</p><p><b>title</b>: MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-11-01 10:20:00+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 ComparativeEvidence}\">ComparativeEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><h3>RelatedArtifacts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style=\"display: none\">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><p><b>assertion</b>: </p><div><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: population</p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes</p>\n</div><p><b>note</b>: population</p><p><b>observed</b>: <a href=\"Group-236947.html\">Adults with type 2 diabetes and CVD and CKD</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: exposure</p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category</b>: GLP-1 RA</p><p><b>description</b>: </p><div><p>GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</p>\n</div><p><b>note</b>: exposure</p><p><b>observed</b>: <a href=\"EvidenceVariable-236950.html\">GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: outcome</p><p><b>description</b>: </p><div><p>Serious hyperglycaemia</p>\n</div><p><b>note</b>: outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-236974.html\">Serious hyperglycaemia</a></p></blockquote><p><b>synthesisType</b>: <span title=\"Codes:\">SYSTEMATIC_REVIEW</span></p><p><b>studyDesign</b>: <span title=\"Codes:{http://hl7.org/fhir/study-design SEVCO:01003}\">randomized assignment</span></p><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>Risk Difference 0.5% (CI95 -0.2% to 1.9%)</p>\n</div><p><b>statisticType</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/statistic-type 0000424}\">Risk Difference</span></p><p><b>quantity</b>: 0.005</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>NumberOfStudies</b></td><td><b>NumberOfParticipants</b></td></tr><tr><td style=\"display: none\">*</td><td>1</td><td>463</td></tr></table><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">CI95</span></td><td>-0.002-0.019</td></tr></table></blockquote><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>OR 1.48 (CI95 0.75 to 2.93)</p>\n</div><p><b>statisticType</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/statistic-type C16932}\">Odds Ratio</span></p><p><b>quantity</b>: 1.48</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>NumberOfStudies</b></td><td><b>NumberOfParticipants</b></td></tr><tr><td style=\"display: none\">*</td><td>1</td><td>463</td></tr></table><h3>AttributeEstimates</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">CI95</span></td><td>0.75-2.93</td></tr></table></blockquote><blockquote><p><b>certainty</b></p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type Overall}\">Overall certainty</span></p><p><b>rating</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/27834 RJCS-2003}\">High certainty</span></p><h3>Subcomponents</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Rating</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Risk of Bias</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Inconsistency</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Indirectness</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Imprecision</span></td><td><span title=\"Codes:\">NONE</span></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Publication Bias</span></td><td><span title=\"Codes:\">NOTSET</span></td></tr></table></blockquote></div>"
},
"url" : "https://fevir.net/resources/Evidence/236975",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "236975",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "outcomeId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "313963"
},
{
"type" : {
"text" : "picoId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "85798"
},
{
"type" : {
"text" : "sectionId"
},
"system" : "https://app.magicapp.org/#/guidelines",
"value" : "73215"
},
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44.22.66"
}
],
"version" : "2.0.0-ballot",
"name" : "Serious_hyperglycaemiafrom_MAGICapp_313963",
"title" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"status" : "active",
"date" : "2024-11-01T10:20:00+00:00",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"author" : [
{
"name" : "Computable Publishing®: MAGIC-to-FEvIR Converter"
}
],
"useContext" : [
{
"code" : {
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "evidence-communication",
"display" : "Evidence Communication"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "ComparativeEvidence",
"display" : "ComparativeEvidence"
}
]
}
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"relatedArtifact" : [
{
"type" : "part-of",
"resourceReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-conversion-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
}
],
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"assertion" : "There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.",
"variableDefinition" : [
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
"valueCode" : "population"
}
],
"description" : "Adults with type 2 diabetes",
"note" : [
{
"text" : "population"
}
],
"observed" : {
🔗 "reference" : "Group/236947",
"type" : "Group",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-population-group-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Adults with type 2 diabetes and CVD and CKD"
}
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
"valueCode" : "exposure"
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category",
"valueString" : "GLP-1 RA"
}
],
"description" : "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
"note" : [
{
"text" : "exposure"
}
],
"observed" : {
🔗 "reference" : "EvidenceVariable/236950",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-group-assignment-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"
}
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code",
"valueCode" : "outcome"
}
],
"description" : "Serious hyperglycaemia",
"note" : [
{
"text" : "outcome"
}
],
"observed" : {
🔗 "reference" : "EvidenceVariable/236974",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313963",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "Serious hyperglycaemia"
}
}
],
"synthesisType" : {
"text" : "SYSTEMATIC_REVIEW"
},
"studyDesign" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/study-design",
"code" : "SEVCO:01003",
"display" : "randomized assignment"
}
]
}
],
"statistic" : [
{
"description" : "Risk Difference 0.5% (CI95 -0.2% to 1.9%)",
"statisticType" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/statistic-type",
"version" : "5.0.0-cibuild",
"code" : "0000424",
"display" : "Risk Difference"
}
]
},
"quantity" : {
"value" : 0.005
},
"sampleSize" : {
"numberOfStudies" : 1,
"numberOfParticipants" : 463
},
"attributeEstimate" : [
{
"type" : {
"text" : "CI95"
},
"range" : {
"low" : {
"value" : -0.002
},
"high" : {
"value" : 0.019
}
}
}
]
},
{
"description" : "OR 1.48 (CI95 0.75 to 2.93)",
"statisticType" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/statistic-type",
"version" : "5.0.0-cibuild",
"code" : "C16932",
"display" : "Odds Ratio"
}
]
},
"quantity" : {
"value" : 1.48
},
"sampleSize" : {
"numberOfStudies" : 1,
"numberOfParticipants" : 463
},
"attributeEstimate" : [
{
"type" : {
"text" : "CI95"
},
"range" : {
"low" : {
"value" : 0.75
},
"high" : {
"value" : 2.93
}
}
}
]
}
],
"certainty" : [
{
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "Overall",
"display" : "Overall certainty"
}
]
},
"rating" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/27834",
"code" : "RJCS-2003",
"display" : "High certainty"
}
]
},
"subcomponent" : [
{
"type" : {
"text" : "Risk of Bias"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Inconsistency"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Indirectness"
},
"rating" : {
"text" : "NOTSET"
}
},
{
"type" : {
"text" : "Imprecision"
},
"rating" : {
"text" : "NONE"
}
},
{
"type" : {
"text" : "Publication Bias"
},
"rating" : {
"text" : "NOTSET"
}
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-01
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change